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Nahid H Ahmed1*, Kamaldeen Baba1,2, Cornelis Clay1, Ruth Lekalakala1,2 and Anwar A Hoosen1,2Abstract
Background: The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our
hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant
organisms was recently licensed in South Africa.
Aim: The aim of this study was to evaluate the in vitro activity of tigecycline against carbapenem resistant
A. baumannii complex.
Methods: Consecutive clinical isolates of carbapenem resistant A. baumannii complex were collected between
February and July 2010. Species identification and susceptibility testing was performed by Vitek-2 colorimetric
compact system with Advanced Expert System (AES). Strains were tested for carbapenemase production by the
modified Hodge test, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
Results: A total of 232 carbapenem resistant clinical isolates of A. baumannii complex were collected over the six
months study period; 217 (93.5%) of these were modified Hodge test positive. All isolates were susceptible to
colistin and 174 (78%) susceptible to amikacin whilst 20 (9%) were susceptible to ciprofloxacin. For tigecycline 169
(75.8%) were fully susceptible, 37 (16.6%) intermediately resistant and only 17 (7.6%) were fully resistant. None of the
carbapenem resistant isolates were susceptible to ampicillin, amoxicillin/clavullanic acid, piperacillin/tazobactam,
cefuroxime, cefuroxime axetil, cefoxitin, cefepime or nitrofurantoin.
Conclusion: All carbapenem resistant isolates were found to be fully susceptible to colistin; amikacin and
tigecycline susceptibility was 78% and 76% respectively. Treatment options for infections due to carbapenem and
multi-drug resistant A. baumannii organisms are limited and hence tigecycline and amikacin may be considered.
The properties of tigecycline i.e. stability, safety, low toxicity, non cross-resistance with other antibiotics and its
efficacy against multi-drug resistant A. baumannii isolates make it a good choice. However, ongoing monitoring of
A. baumannii susceptibility to tigecycline is needed.
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Glycylcyclines, are novel group of drugs which are
tetracycline analogues that circumvent resistant
mechanisms against tetracycline [1]. Tigecycline is the
first member of the glycylcyclines group to be launched
and acts on the ribosomes by inhibiting protein synthesis
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reproduction in any medium, provided the orimportant nosocomial pathogens such as Escherichia coli,
Klebsiella pneumoniae and multi drug resistant (MDR)
A. baumannii, it is also active against extended-spectrum
beta-lactamase (ESBL) producing strains [1]. Tigecycline
does not present cross-resistance with other antibiotics
such as β lactams or fluoroquinolones [3].
A. baumannii has emerged as an important, troublesome
nosocomial pathogen globally. Its clinical significance is due
to its ability to easily acquire resistance determinants, mak-
ing it one of the organisms threatening the currently avail-
able therapeutic panel of antimicrobials [4]. Furthermore,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Antimicrobial susceptibility profile* of








Ampicillin - - 100.0% (≥ 32)
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periods in the hospital environment, potentiating its ability
for nosocomial spread. In the intensive care units (ICU)
setting the most vulnerable patients are usually those
with ventilator associated pneumonia [4]. The use of
carbapenems to treat A. baumannii infection has
resulted in outbreaks of infection with carbapenem-resistant
Acinetobacter species [5].
In recent years in South Africa, we have observed a
marked increase in the number of ICU infections due
to MDR) A. baumannii (unpublished National Anti-
biotic Surveillance Forum data). This raises a thera-
peutic challenge and with the recent licensing in South
Africa of tigecycline, a new glycylcycline with expanded
broad spectrum of activity against MDR organisms we
have an additional option for management of such
infections. This study was undertaken to evaluate the
in vitro activity of tigecycline against carbapenem resist-
ant A. baumannii from patients attending the Steve
Biko Academic Hospital Complex in Pretoria.
Results
During the 6 month period carbapenem resistant A.
baumannii complex isolates were cultured from 232
patients. Patient information and specimen types are
shown in Table 1. Fifty nine percent of patients were
males 48.7%, were in the 31-59 year age group and
62.5% were from the ICU. The less than 10 year age
group accounted for 30 (12.9%) patients.
From the 232 carbapenem resistant A. baumannii
complex isolates, a total of 217 (93.5%) were modified
Hodge test positive.Table 1 Patient and specimen information (N=232)
Age groups
≤ 30 years 87 (37.5%)
31–59 years 113 (48.7%)









Blood Culture 20 (8.6%)
Urine 15 (6.5%)
CVP tips** 11 (4.7%)
Other*** 37 (15.9%)
*ETA = Endo-Tracheal Aspirates.
**CVP =Central Venous Puncture.
***Other = includes wound swabs, tissues and effusions.Sixty four percent of the specimens were from endo-
tracheal aspirates. Table 2 shows the antimicrobial suscep-
tibility profile of all the carbapenem resistant A. baumannii
complex isolates. All isolates were susceptible to colistin
and 174 (78%) were susceptible to amikacin whilst only 20
(9%) were susceptible to ciprofloxacin. For tigecycline 169
(75.8%) were fully susceptible (≤ 0.25 μg/ml), 37 (16.6%)
were shown as intermediately resistant (1–7 μg/ml) and
only 17 (7.6%) were resistant (≥ 8 μg/ml). None of the
carbapenem resistant isolates were susceptible to ampicil-
lin, amoxicillin/clavulanic acid, piperacillin/tazobactam,
cefuroxime, cefuroxime axetil, cefoxitin, cefepime and
nitrofurantoin.
Discussion
MDR A. baumannii has emerged as a major cause of
hospital acquired infections [5]. Infections caused by
these MDR organisms are difficult to treat as only few
therapeutic antimicrobial options are available and their
eradication from the hospital environment is problem-
atic [6].
Tigecycline, approved by the US Food and Drug Ad-
ministration (FDA) for the treatment of complicated
intra-abdominal and complicated skin and soft tissue
infections [6,7], has been shown to have adequateAmoxicillin/clavulanic acid - - 100.0% (≥ 32)
Piperacillin/tazobactam - - 100.0% (≥ 32)
Cefuroxime - - 100.0% (≥ 32)
Cefuroxime Axetil - - 100.0% (≥ 32)
Cefoxitin - - 100.0% (≥ 32)
Cefotaxime - - 100.0% (≥ 32)
Nitrofurantoin - - 100.0% (≥ 32)
Meropenem - - 100.0% (≥ 16)
Imipenem - - 100.0% (≥ 16)
Cefepime - 0.4% (9 - 31) 99.6% (≥ 32)
Nalidixic acid 8.1% (≤ 2) - 91.9% (≥ 32)
Ciprofloxacin 9.0% (≤ 1) - 91.0% (≥ 4)
Trimethoprim/
Sulfamethoxazole
12.6% (≤ 20) - 87.4% (≥ 320)
Ceftazidime 7.6% (≤ 8) 12.6% (9-31) 79.8% (≥ 64)
Gentamicin 9.4% (≤ 1) 12.6% (2-15) 78.0% (≥ 16)
Amikacin 78.0% (≤ 16) 11.7% (17-63) 10.3% (≥ 64)
Tigecycline 75.8% (≤ 0.25) 16.6% (1-7) 7.6% (≥ 8)
Colistin 100.0% (≤ 2) - -
* According to CLSI guidelines 2010 (MIC values in μg/ml).
- = none.
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cluding A. baumannii. This agent may well become an
attractive option for the treatment of infections caused
by MDR A. baumannii [8].
Tigecycline proved to be safe, well tolerated and effective
against a broad spectrum of key community-acquired bac-
terial pneumonia pathogens, and because it is available in
an intravenous (IV) formulation its usage would likely be
limited largely to patients requiring hospitalization [9,10].
The most frequently reported adverse events with tigecy-
cline were nausea, vomiting, diarrhoea, local IV-site reac-
tion, fever, abdominal pain, and headache [11]. Recent
systemic review also found higher mortality with the use of
tigecycline making it the last-resort drug in the manage-
ment of MDR infections [12].
In this study, tigecycline showed very good in vitro ac-
tivity (MIC ≤ 0.25 μg/ml) against 75% of carbapenem re-
sistant A. baumannii strains with only 7% being fully
resistant to tigecycline (MIC ≥ 8 μg/ml). This is a slightly
lower than what was reported from Taiwan and the
USA; where around 85% of the isolates were susceptible
to tigecycline [13,14]. However, a recent study from India
showed 29% of MDR Acinetobacters were resistant to
tigecycline. This could be due to the fact that tigecycline
has been in use in India for several years [15].
In keeping with the report by Molina et al. [16], MDR
A. baumannii isolates were also shown to be 100% sus-
ceptible to colistin. However, the issue of nephrotoxicity
is a challenge in the management of this infection with
an agent such as colistin [17].
All carbapenem resistance isolates were found to be
fully susceptible to colistin; amikacin and tigecycline sus-
ceptibility was 78% and 76% respectively.
The limitation of our study is that it was conducted at
the National Health Laboratory Service NHLS, Tshwane
district; the laboratory receives specimens for culture
and drug susceptibility testing from 5 tertiary-academic,
provincial and district hospitals however, our results
might not be applicable to other hospitals in Pretoria.
Conclusion
Treatment options for infections due to carbapenem and
multi-drug resistant A. baumannii organisms are limited
and hence tigecycline and amikacin may be considered
options for such infections. The properties of tigecycline i.e.
stability, safety, low toxicity, non cross-resistance with other
antibiotics and its efficacy against MDR A. baumannii iso-
lates make it a good choice. However, ongoing monitoring
of A. baumannii susceptibility to tigecycline is needed.
Material and methods
Study design and sampling
A prospective descriptive study was conducted at the
National Health Laboratory Service NHLS, Tshwanedistrict; the laboratory receives specimens for culture
and drug susceptibility testing from the Steve Biko Aca-
demic Hospital, Kalafong hospital, Tshwane district
hospital, Mamelodi hospital, Tshwane metro clinics and
the Department of Medical Microbiology University of
Pretoria. Consecutive clinical isolates were collected
from 232 patients who had carbapenem resistant A.
baumannii complex infections, over a six month period
i.e. between February and July 2010. During this period
539 carbapenem resistant A. baumannii were isolated
from the 232 patients. The duplicate isolates from the
same patients were excluded for analysis. There was no
need for patients consent as the isolates used in this
study were not linked to individual patients. This study
was approved by the University of Pretoria, faculty of
Health Sciences, Ethical committee under this number:
(86/2011).
Identification and susceptibility testing
The VITEK-2 calorimetric compact system with
Advanced Expert System (AES), (bioMerieux, France)
[18], was used for the identification of isolates and for
the antimicrobial susceptibility testing for the carbape-
nems, tigecycline and other antibiotics by using the using
GN identification cards and AST-N133 cards. A. baumannii
ATCC BAA 747 was used as a control.
The following antibiotics were tested: imipenem, merope-
nem, ampicillin, amoxicillin/clavulanic acid, piperacillin/
tazobactam, cefuroxime, cefuroxime axetil, cefoxitin,
cefotaxime, ceftazidime, cefepime, amikacin, gentamicin,
nalidixic acid, ciprofloxacin, tigecycline, nitrofurantoin,
colistin and trimethoprim/sulfamethoxazole. The Clinical
and Laboratory Standards Institute (CLSI, 2010) [19]
guidelines were used for interpretation.
The modified Hodge test [19] was done to detect the
presence of carbapenemases. The test was performed by
preparing a 5 ml of 0.5 McFarland standard suspensions
from an overnight culture of indicator organism E. coli
ATCC 25922 and diluted in 1:10, and these were used to
swab inoculate the surface of the Muller-Hinton agar plate.
After drying the surface, a 10-μg ertapenem disk (Becton
Dickinson) was placed at the centre, thereafter 3 colonies
of test organism grown overnight on a blood agar plate
was heavily streaked from the centre (edge of the disc) to
the periphery of the plates, then the plate was incubated
overnight. The Hodge test is interpreted as positive by the
presence of distortion of the inhibition zone.
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